Uric acid levels in blood are associated with clinical outcome in soft-tissue sarcoma patients

Clinical Chemistry and Laboratory Medicine

Volumn 53, Issue 3, 2015, Pages 493-497

  Szkandera, Joanna ^a   Gerger, Armin ^a   Liegl Atzwanger, Bernadette ^a   Stotz, Michael ^a   Samonigg, Hellmut ^a   Ploner, Ferdinand ^a   Stojakovic, Tatjana ^a   Gary, Thomas ^a   Leithner, Andreas ^a   Pichler, Martin ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

prognostic marker; soft tissue sarcoma; uric acid levels

Indexed keywords

ANTINEOPLASTIC AGENT; URIC ACID;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; BLOOD SAMPLING; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER SURGERY; COLORIMETRY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FIBROMYXOSARCOMA; HAZARD RATIO; HISTOPATHOLOGY; HUMAN; KAPLAN MEIER METHOD; LEIOMYOSARCOMA; LIPOSARCOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT FIBROUS HISTIOCYTOMA; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SERUM; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA; TREATMENT OUTCOME; TUMOR VOLUME; UNIVARIATE ANALYSIS; URIC ACID BLOOD LEVEL; BLOOD; RECEIVER OPERATING CHARACTERISTIC; SARCOMA;

FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; ROC CURVE; SARCOMA; TREATMENT OUTCOME; URIC ACID;

EID: 84923068657     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2014-0486     Document Type: Article

References (20)

1. Cormier JN, Pollock RE. Soft tissue sarcomas. CA Cancer J Clin 2004;54:94-109.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
3. Scaife CL, Pisters PW. Combined-modality treatment of localized soft tissue sarcomas of the extremities. Surg Oncol Clin N Am 2003;12:355-68.
4. Szkandera J, Gerger A, Liegl-Atzwanger B, Absenger G, Stotz M, Friesenbichler J, et al. The lymphocyte/monocyte ratio predicts poor clinical outcome and improves the predictive accuracy in patients with soft tissue sarcomas. Br J Cancer 2014;110:435-40.
5. Szkandera J, Gerger A, Liegl-Atzwanger B, Absenger G, Stotz M, Samonigg H, et al. Validation of the prognostic relevance of plasma C-reactive protein levels in soft-tissue sarcoma patients. Br J Cancer 2013;109:2316-22.
6. Kattan MW, Leung DH, Brennan MF. Postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol 2002;20:791-6.
7. Yamauchi T, Negoro E, Lee S, Takai M, Matsuda Y, Takagi K, et al. A high serum uric acid level is associated with poor prognosis in patients with acute myeloid leukemia. Anticancer Res 2013;33:3947-51.
8. Shin HS, Lee HR, Lee DC, Shim JY, Cho KH, Suh SY. Uric acid as a prognostic factor for survival time: a prospective cohort study of terminally ill cancer patients. J Pain Symptom Manage 2006;31:493-501.
9. Dziaman T, Banaszkiewicz Z, Roszkowski K, Gackowski D, Wisniewska E, Rozalski R, et al. 8-Oxo-7, 8-dihydroguanine and uric acid as efficient predictors of survival in colon cancer patients. Int J Cancer 2014;134:376-83.
10. Fletcher CD, Bridge JA, Hogendoorn P, Mertens F, editors. WHO classification of tumours of soft tissue and bone, 4th ed., vol. 5. Lyon: IARC Press, 2013.
11. Coindre JM. Grading of soft tissue sarcomas: review and update. Arch Pathol Lab Med 2006;130:1448-53.
12. Liegl-Atzwanger B, Hofmann G, Leithner A, Beham A. Undiffer-entiated high-grade pleomorphic sarcoma (UHPS): diagnostic criteria, differential diagnosis, and treatment. An attempt to erasure the misnomer MFH. Eur Surg 2009;41:143-9.
13. Absenger G, Szkandera J, Stotz M, Postlmayr U, Pichler M, Ress AL, et al. A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II and III colon cancer patients. Br J Cancer 2013;109:395-400.
14. Strasak AM, Lang S, Kneib T, Brant LJ, Klenk J, Hilbe W, et al. Use of penalized splines in extended Cox-type additive hazard regression to flexibly estimate the effect of time-varying serum uric acid on risk of cancer incidence: a prospective, population-based study in 78, 850 men. Ann Epidemiol 2009;19:15-24.
15. Chaudhary K, Malhotra K, Sowers J, Aroor A. Uric acid-key ingredient in the recipe for cardiorenal metabolic syndrome. Cardiorenal Med 2013;3:208-20.
16. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003;425:516-21.
17. Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant-and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA 1981;78:6858-62.
18. Jackson AL, Loeb LA. The contribution of endogenous sources of DNA damage to the multiple mutations in cancer. Mutat Res 2001;477:7-21.
19. Storz P. Reactive oxygen species in tumor progression. Front Biosci 2005;10:1881-96.
20. Troppan K, Deutsch A, Gerger A, Stojakovic T, Beham-Schmid C, Wenzl K, et al. The derived neutrophil to lymphocyte ratio is an independent prognostic factor in patients with diffuse large B-cell lymphoma. Br J Cancer 2014;110:369-74.